Novo Nordisk on Monday lowered the direct-to-consumer prices of its weight loss drug Wegovy and diabetes treatment Ozempic in a challenge to Eli Lilly’s Zepbound after President Donald Trump announced a deal with the pharmaceutical firms to reduce the U.S. price tag of the popular drugs.
Source: Original Article